112 related articles for article (PubMed ID: 6368960)
1. Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: a randomized study comparing different times and routes of administration of Corynebacterium parvum.
Fritze D; Massner B; Becher R; Kaufmann M; Illiger HJ; Hartlapp J; Queisser W; Abel U; Edler L; Mayr AC
Klin Wochenschr; 1984 Feb; 62(4):162-7. PubMed ID: 6368960
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer.
Fritze D; Becher R; Massner B; Kaufmann M; Bruntsch U; Gallmeier WM; Mayr AC; Drings P; Abel U; Edler L; Jungi WF; Queisser W; Senn HJ
Klin Wochenschr; 1982 Jun; 60(12):593-8. PubMed ID: 7109499
[TBL] [Abstract][Full Text] [Related]
3. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer.
Fritze D; Queisser W; Schmid H; Kaufmann M; Massner B; Westerhausen M; Schmidt R; Edler L; Abel U
Onkologie; 1986 Dec; 9(6):305-12. PubMed ID: 2950359
[TBL] [Abstract][Full Text] [Related]
5. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.
Powles TJ; Jones AL; Judson IR; Hardy JR; Ashley SE
Br J Cancer; 1991 Aug; 64(2):406-10. PubMed ID: 1892775
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Hortobagyi GN; Yap HY; Wiseman CL; Blumenschein GR; Buzdar AU; Legha SS; Gutterman JU; Hersh EM; Bodey GP
Cancer Treat Rep; 1980 Jan; 64(1):157-9. PubMed ID: 6991103
[TBL] [Abstract][Full Text] [Related]
7. [Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)].
Mayr AC; Senn HJ; Gallmeier WM; Bruntsch U; Becher R; Drings P; Fritze D; Kaufmann M; Queisser W; Kempgens U
Dtsch Med Wochenschr; 1979 Dec; 104(49):1739-43. PubMed ID: 510206
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy versus chemoimmunotherapy with levamisole or Corynebacterium parvum in advanced lung cancer.
Chahinian AP; Goldberg J; Holland JF; Reisman A; Jaffrey IS; Mandel EM
Cancer Treat Rep; 1982 Jun; 66(6):1291-7. PubMed ID: 6282455
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
[TBL] [Abstract][Full Text] [Related]
10. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy using the CMF regimen (cyclophosphamide, methotrexate, and 5-fluorouracil) and the VAC protocol (vincristine, adriamycin and cyclophosphamide) in patients with advanced breast cancer].
Glińska H; Zulichowska J; Radziszewska J; Sukiennik-Siuda M; Trabka E
Nowotwory; 1987; 37(3):251-61. PubMed ID: 3438177
[No Abstract] [Full Text] [Related]
12. Intravenous Corynebacterium parvum: an adjunct to chemotherapy for resistant advanced ovarian cancer.
Rao B; Wanebo HJ; Ochoa M; Lewis JL; Oettgen HF
Cancer; 1977 Feb; 39(2):514-26. PubMed ID: 837334
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy of metastasizing breast cancer].
Wascher H
Wien Med Wochenschr; 1985 Dec; 135(23-24):590-4. PubMed ID: 3841627
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
Carmo-Pereira J; Costa FO; Henriques E
Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
[TBL] [Abstract][Full Text] [Related]
15. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Smith IE; Powles TJ
Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
[TBL] [Abstract][Full Text] [Related]
16. Prolonged adjuvant chemotherapy in breast cancer. The Scandinavian Adjuvant Chemotherapy Study 2.
Nissen-Meyer R; Høst H; Kjellgren K
Acta Oncol; 1989; 28(6):903-6. PubMed ID: 2611040
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
[TBL] [Abstract][Full Text] [Related]
18. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
20. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
